Literature DB >> 10493568

Association between plasma homocysteine concentrations and cardiac hypertrophy in end-stage renal disease.

J Blacher1, K Demuth, A P Guerin, C Vadez, N Moatti, M E Safar, G M London.   

Abstract

In patients with end-stage renal disease, plasma homocysteine and cardiac mass are both increased and considered independent risk predictors for cardiovascular-specific morbidity and mortality. In order to establish a relationship between these two parameters, we determined cardiac mass and plasma homocysteine in 75 patients with end-stage renal disease undergoing chronic hemodialysis. We observed a statistically significant positive association between plasma homocysteine and cardiac mass index or either of its components. This was observed even after adjustment for age, sex, systolic blood pressure and hematocrit (p = 0.0027). The adjusted odds ratio for left ventricular hypertrophy was 6.6 (95% confidence interval 1.3-32.8) for subjects with the highest versus the lowest plasma homocysteine concentrations. This cross-sectional study is the first to show a statistical link between plasma homocysteine and cardiac structure, independently of mechanical factors. High plasma homocysteine concentrations are associated with an increased adjusted risk of left ventricular hypertrophy in end-stage renal disease patients.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10493568

Source DB:  PubMed          Journal:  J Nephrol        ISSN: 1121-8428            Impact factor:   3.902


  10 in total

1.  Risk factors for development of cardiovascular complications in patients with chronic renal disease and diabetic nephropathy.

Authors:  Amra Mataradzija; Halima Resić; Senija Rasić; Nihad Kukavica; Fahrudin Masnić
Journal:  Bosn J Basic Med Sci       Date:  2010-04       Impact factor: 3.363

2.  MicroRNAs are involved in homocysteine-induced cardiac remodeling.

Authors:  Paras K Mishra; Neetu Tyagi; Soumi Kundu; Suresh C Tyagi
Journal:  Cell Biochem Biophys       Date:  2009-08-11       Impact factor: 2.194

3.  Homocysteine induces cardiomyocyte dysfunction and apoptosis through p38 MAPK-mediated increase in oxidant stress.

Authors:  Xu Wang; Lei Cui; Jacob Joseph; Bingbing Jiang; David Pimental; Diane E Handy; Ronglih Liao; Joseph Loscalzo
Journal:  J Mol Cell Cardiol       Date:  2011-12-29       Impact factor: 5.000

4.  Homocysteine and left ventricular hypertrophy in children with chronic renal failure.

Authors:  Hakan M Poyrazoğlu; Ruhan Düşünsel; Figen Narin; Zübeyde Gündüz; Nazmi Narin; Musa Karakükçü; Fulya Tahan
Journal:  Pediatr Nephrol       Date:  2003-12-05       Impact factor: 3.714

Review 5.  [Atherosclerosis and uremia: signifance of non-traditional risk factors].

Authors:  Walter H Hörl
Journal:  Wien Klin Wochenschr       Date:  2003-04-30       Impact factor: 1.704

6.  Traditional and "new" cardiovascular risk markers and factors in pediatric dialysis patients.

Authors:  Mahmut Civilibal; Salim Caliskan; Huseyin Oflaz; Lale Sever; Cengiz Candan; Nur Canpolat; Ozgur Kasapcopur; Zehra Bugra; Nil Arisoy
Journal:  Pediatr Nephrol       Date:  2007-03-06       Impact factor: 3.714

7.  Prognostic value of homocysteine and highly sensitive cardiac troponin T in children with acute heart failure.

Authors:  Doaa El-Amrousy; Samir Hassan; Hossam Hodeib
Journal:  J Saudi Heart Assoc       Date:  2017-12-02

8.  Induction of apoptosis and autosis in cardiomyocytes by the combination of homocysteine and copper via NOX-mediated p62 expression.

Authors:  Ran Yin; Huan Wang; Chun Li; Lulu Wang; Songqing Lai; Xianhe Yang; Daojun Hong; Wan Zhang
Journal:  Cell Death Discov       Date:  2022-02-21

9.  Hyperhomocysteinemia Promotes Cardiac Hypertrophy in Hypertension.

Authors:  Yawen Deng; Zhitong Li; Xiangbo An; Rui Fan; Yao Wang; Jiatian Li; Xiaolei Yang; Jiawei Liao; Yunlong Xia
Journal:  Oxid Med Cell Longev       Date:  2022-08-22       Impact factor: 7.310

10.  The neurotoxicity of nitrous oxide: the facts and "putative" mechanisms.

Authors:  Sinead Savage; Daqing Ma
Journal:  Brain Sci       Date:  2014-01-28
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.